Governance

The supervisory and executive boards of Clean Biologics composed of biomanufacturing and financial experts are involved and determined to make sure the group and its subsidiaries maintain this highest standards of ethical practices.

joseph-jammal

Joseph
Jammal

Discover the biography

Joseph Jammal

CEO

Joseph Jammal brings a strong international experience and in-depth knowledge of the IVD & Life Science fields.

Prior to this appointment, Joseph served as President & CEO of Cisbio Bioassays, an international biotechnology company specialized in products and technologies used for in vitro diagnostics and drug discovery. Joseph led the group’s transformation optimizing its most profitable and promising businesses and emphasizing on R&D. He brought the Life Science business to a sustainable organic double-digit growth strongly reshaping the company’s culture and driving a turnaround in the United States.

Prior to Cisbio Joseph worked at bioMérieux for over 15 year holding various top and broad management positions. He served in his last position as VP Worldwide Commercial Operations & Customer Service at bioMérieux Industry Business Unit where he reorganized the global Business Development (Sales, Marketing and Customer service). Previously, he was VP Global Food Microbiology Franchise, leading the Food Diagnostics Business in all fields, driving objectives cross-border in a matrix based international environment.

« The destination, of course… but the pleasure and the satisfaction of the journey as well. Bringing together the women, the men, and the teams to support and bring to life a story of entrepreneurship that will provide to all involved the pride and the joy of an unrivalled adventure. »

olivier-boisteau

Olivier
Boisteau

Discover the biography

Olivier Boisteau

Co-Founder and Strategic Advisor

Co-Founder and Strategic Advisor, Cell Pharmacology Engineer, Ecole Pratique des Hautes Etudes, Paris IV Panthéon Sorbonne University.

As part of his degree at Sorbonne University, Olivier joins the INSERM (French National Institute of Health & Medical Research) to carry out research relating to a thesis work on colon cancer vaccination. After this initial work, he joins the team of Yannick Jacques, PhD, as engineer to a program focusing on the development of agonist/antagonist recombinant proteins to cytokine receptors. This development work was part of a larger European program. Entrepreneur at heart, Olivier then decides to venture into the business world together with Frédéric Henry and Marc Meichenin to build a company based on the expertise of mycoplasma eradication in cell cultures: Clean Cells is thus created on July 31st 2000. Olivier is also a member of the Atlanpole Biotherapies cluster’s board of directors and of AFFSSI (French Association of Service and Technological Innovation Companies).

« My role as Co-Founder and Strategic Advisor is to assist the executive committee in building the company in the years to come. With this in mind, it is crucial to not forget the path taken up to here in order to build a better future and root the company development into founding values. Biotech companies take part in the improvement of Life and our role as service provider is an essential one to help others develop biopharmaceuticals which are vital to humankind. I will always be closely watching to check that the company values are shared by all our collaborators for whom I have great respect and love. Nothing can be made possible without them, and they are involved and engaged. They uphold our involvement in the development of therapeutic advances. My role in relation to them is to support and assist them. Each one of them is an essential link to the success of the company and our goals to better Life can only be reached together. »

marc-meichenin

Marc
Meichenin

Discover the biography

Marc Meichenin

Co-Founder and CSO

Co-Founder, Board member of Clean Biologics and Chief Scientific Officer, Doctor of Biological Sciences, University of Nantes.

It was at Inserm, where he did his thesis on tumour biology, that he was led to work on cell injection in animals. Very quickly, Marc saw the importance of mycoplasma detection and focused his efforts on it, until he quickly became a reference for the institution’s researchers. In 2000, he joined the creation of Clean Cells with his two friends Olivier Boisteau and Frédéric Henry. Their joint efforts allow the development of a service company with an international aura.

Active member of ACTIP for many years and more recently appointed expert in the framework of the “Grand Défi Bioproduction”, he participates in the development of Bioproduction in France.

Since the creation of the Clean Biologics Group, which includes Clean Cells and Naobios, he brings to both entities his technical and regulatory expertise as Scientific Director.

« As Scientific Director, my mission is to ensure, day after day, the maintenance of the high level of our services in accordance with the regulations. I act as the technical interface with our customers by advising and developing appropriate protocols. I am also involved in the management of any issues (OOS, interfering effects of sample) during the tests performed at Clean Cells and Naobios. As Scientific Director and Board member, I participate in the Group's development strategy while ensuring that the values that have made us successful are maintained. »

eric-le-forestier

Eric
Le Forestier

Discover the biography

Eric Le Forestier

Managing Director of Naobios

Eric is the Managing Director of Naobios and brings 20 years of international experience across the Biotech and Pharmaceutical Industry.

Prior to joining Naobios, Eric spent 12 years with GSK Vaccines; his last position was Head of infrastructure of the QC laboratories in Belgium.

Eric has worked as well with Aquitaine Pharm International (a CMO specialized in aseptic fill and finish of highly potent APIs, previously part of Pierre Fabre Laboratories) and Immuno-Design Molecules (a Biotech developing cellular therapies against cancer, now part of Takeda Oncology).

Eric has lived and worked in France, UK, US, Belgium and Japan.

He holds a PharmD in Industrial Pharmacy from Nantes University, an MS in IT applied to Life Sciences from Paris University and a Global Executive MBA from INSEAD.

« As General Manager of Naobios, my role is to support my team to provide our expertise in process development and clinical grade production of viruses to our worldwide customers. Our objective is to provide the best level of quality and responsiveness, in an atmosphere of trust and continuous innovation. »

stephane-vapillon

Stéphane
Vapillon

Discover the biography

Stéphane Vapillon

CFO

Stéphane joined CLEAN BIOLOGICS in January 2019 as CFO. He is managing Finance, Accounting, Financial Control, IT/IS, Legal, and HR for the Group.

He spent 10 years at DELOITTE and KPMG as successively IS/IT auditor, IS consultant, internal audit / internal control / risk management consultant, while taking charge of accounting expertise and statutory auditing functions.

Stéphane then acted for several fast-growing family-owned groups such as: SERIS Group, a European player in private security and safety, where he was advisor to the CEO & main shareholder, Director of Financial Operations & Group Acquisitions, and member of the Strategic Committee; or BRIAND Group, a key player in the construction.

Stéphane also worked as CFO of IMAYE GRAPHIC/EASYCOM, one of the three French leaders in paper and digital communications; where he managed a successful and life-saving treasury improvement and a quick return to profitability.

Stéphane then co-managed the IPO of COGELEC on Euronext.

Stéphane Vapillon also has extensive experience in acquisitions (over 20 audited, acquired and consolidated companies), in several countries.

Stéphane holds a degree in audit finance from the ESSCA Business School, a Master’s level diploma in Accountancy, a Specialised Master in IS from the ESSEC/TELECOM PARIS, the CIA, the CISA, and completed the KPMG Executive Programme at the ESCP EAP.

« As CFO, my job is to master the 3 fundamental pillars (profitability, liquidity and debt), optimize cash position, ensure the financing of our growth, establish monthly closing, prepare useful reporting to all stakeholders, manage legal risks, contribute to management of operations, at both companies and group levels, manage projects, follow up action plans, impulse change management when required, and of course with the day to day objective to create value with the involvement of my dear teams (accounting, finance, tax, legal, IT/IS, HR, procurement & logistics)! »

gildas-bernard

Gildas
Bernard

Discover the biography

Gildas Bernard

Financial controller

Gildas joined CLEAN BIOLOGICS in February 2019 as Financial Controller. He is managing Accounting Team for CLEAN CELLS as well.

He spent 15 years at DECATHLON as successively head of store departments, commercial management control, financial and administrative manager, and store manager while gaining dual experience to link operational and accounting goals.

Subsequently, Gildas worked in different sectors (S.M.E. in sport business, HVAC supply and distribution of local products) as accounting manager and operational director.

Gildas enriched his soft skills interest with a coaching training program.

Gildas holds a degree in accounting and finance.

« As financial controller at Clean Biologics, my role is to ensure consistency between the group strategy and the effective actions of our collaborators. I am thus in contact with the various actors of the group on a daily basis to reach that aim, while leaning on their individual expertise, and also manage the accounting team at Clean Cells. »

francois-pedelaborde

François
Pedelaborde

Discover the biography

François Pedelaborde

Business Development Director

Business Development Director, Molecular Biology Engineer, École Pratique des Hautes Études, University of Paris IV Panthéon Sorbonne.

As part of his studies at the Sorbonne, François joined Inserm UMR601 to carry out research on the identification of molecular markers for the differentiation of brain tumors.
Following this training, in 2006 he joined the Clean Cells team as a Research and Development project manager. During this mission, he was able to support Clean Cells’ customers in their needs for custom analytical development.

In order to be able to offer the best solutions to our customers, François joins the Clean Cells sales team in 2016 to support the commercial development of the company in France and Belgium. Following this experience, he now leads the sales team.

« As part of my role of Business Development Director, I oversee and manage a team of 7 people with whom I promote Clean Cells’ services in France and worldwide. We offer our customers a scientific expertise and an ever-expanding portfolio of services addressing our customers’ needs while maintaining regulatory requirements, which are deeply rooted in our field of activity. »

ludovic-alonzi

Ludovic
Alonzi

Discover the biography

Ludovic Alonzi

Ludovic joined ArchiMed in 2016. He holds over 10 years of experience in M&A. Previously, Ludovic spent four years at M&A boutique Alira Health ( formely know as CMC Consulting), where he was in charge of the Healthcare sector deal flow and, more specifically, the Pharmaceutical and MedTech sectors.

Ludovic is having Board position at Clean Biologics-FR, Polyplus transfection-FR and SMG-Eurotape-NL.

Ludovic graduated with an MSc in Business Administration from ESC (Ecole Supérieure de Commerce) based in Clermont-Ferrand (France). He speaks fluent English.

michael-sneijers

Michael
Sneijers

Discover the biography

Michael Sneijers

Michael is an associate director at ArchiMed. He started his career as an Auditor with Deloitte prior to joining ING Belgium as a Credit Analyst. Michael worked for nine years with Belgian Private Equity firm PMV, developing expertise in direct investments and in funds of funds management.

Michael holds a Master in Applied Economics from KUL, Leuven (Belgium), a Master in Business Administration from ESA Lille (France) and an Executive MBA from IE Business School, Madrid (Spain). Michael is Belgian and speaks fluent French, Dutch and English.

klaus-maleck

Klaus
Maleck

Discover the biography

Klaus Maleck

Klaus joined ArchiMed in 2020 as an Operating Partner. He has over 25 years of experience in management consulting and corporate leadership in the Healthcare industry. At ArchiMed, Klaus is particularly focused on the Biotech sector.

Klaus started his career at the Biotechnology and Genomics Center of Novartis Inc. He then joined McKinsey & Company as a Senior Consultant. He co-founded and lead in his function as CFO BioGenerix AG, the biosimilar business of the ratiopharm group. This was followed by Klaus assuming an executive role at Evotec AG, during which he led a major turn-around, including a Nasdaq listing and numerous corporate development activities. Following this, he joined TETEC AG, a pioneer and market leader in cell therapy development and manufacturing, as CEO.

Klaus holds a PhD in Biochemistry from the Max-Planck Institute and an MBA.

Klaus is a German citizen and speaks fluent English.

annie

Annie
Van Broekhoven

Discover the biography

Annie Van Broekhoven

Annie holds a M.Sc. in Chemistry from the University of Antwerp (Belgium) and obtained a PhD in 1981. After a postdoc at the Weizmann Institute, (Rehovot, Israel) working in the group of Prof. Dr. U. Littauer on the cloning of tubulin and actin, she became involved in the expression, fermentation, purification, and manufacturing of industrial enzymes for Totalfina.

She joined Innogenetics (Ghent) in 1992, first as head of the bioprocess department, later as Vice-President Biologicals responsible for the process and analytical method development and production of Biologicals for diagnostic and therapeutic usage, including cGMP manufacturing.

In 2011 she founded together with Andre Van de Voorde and Martine Vandermarliere, the company Q-Biologicals. Located in Ghent, Q-biologicals is a service company, dedicated to the development of manufacturing processes and cGMP production of biologicals. From 2016 onward, the company is a member of the Amatsi group, part of Eurofins.

During her career she has been involved in various diagnostic and therapeutic projects in several fields, in particular in the field process development and GMP production of recombinant proteins, as well as production of live cells and viruses.

She is currently providing consultancy services in the field of life sciences and she is a non-executive board member of the companies Clean Biologics (Lyon), Biogazelle (Ghent) and Artes (Dusseldorf). She is a Professor emeritus at the University of Antwerp, where she gave a course on Industrial Biotechnology and Microbiology.

OTTO

Otto-Wilhelm
Merten

Discover the biography

Otto-Wilhelm Merten

Otto is non-executive board member of Clean Biologics and works at Miltenyi Biotec globally as gene therapy and vector manufacturing specialist.

Prior to that he was head of the Applied Vectorology and Innovation group at Généthon where he was in charge of the evaluation of the baculovirus system for the production of AAV vectors. In addition, he was the main driver for the development of the GMP manufacturing process for lentiviral vectors at Généthon for the treatment of rare diseases, including WAS (Wiskott Aldrich Syndrome). Between 1986 and 1997, Otto was head of the cell technology laboratory at the Pasteur Institute in Paris. He could show that viruses (rabies, polio, and influenza viruses) can be produced in serum-free media in reactor cultures with virus titers equivalent to traditional production methods. Further activities concerned the development of serum-free media for the production of monoclonal antibodies (mAbs). In 1984, after having terminated his PhD Otto started to work in the hybridoma field at the Sandoz Forschungsinstitut in Vienna/A, in view of mAb production.

Furthermore, Otto performed consulting activities in the field of cell culture, manufacturing of biologicals, and gene therapy and was editor in chief of Cytotechnology for many years. He was board member of ESACT (European Society for Animal Cell Technology) for 16 years and its chairman for 4 years.

Otto earned his PhD in 1984 and his Dipl. Ing. in 1980, both, at the University of Natural Resources and Life Sciences, Vienna/A. In 2000 he became Adjunct Professor at the University of Natural Resources and Life Sciencesin Vienna/A and some years later he received his HDR (‘Habilitation à Diriger les Recherches’) at the University of Evry/Val d’Essonne/F. Otto holds also a Visiting Professorship at ITQB-UNL in Oeiras/Portugal since several years.

joseph-jammal

Joseph
Jammal

Discover the biography

Joseph Jammal

Joseph Jammal brings a strong international experience and in-depth knowledge of the IVD & Life Science fields.

Prior to this appointment, Joseph served as President & CEO of Cisbio Bioassays, an international biotechnology company specialized in products and technologies used for in vitro diagnostics and drug discovery. Joseph led the group’s transformation optimizing its most profitable and promising businesses and emphasizing on R&D. He brought the Life Science business to a sustainable organic double-digit growth strongly reshaping the company’s culture and driving a turnaround in the United States.

Prior to Cisbio Joseph worked at bioMérieux for over 15 year holding various top and broad management positions. He served in his last position as VP Worldwide Commercial Operations & Customer Service at bioMérieux Industry Business Unit where he reorganized the global Business Development (Sales, Marketing and Customer service). Previously, he was VP Global Food Microbiology Franchise, leading the Food Diagnostics Business in all fields, driving objectives cross-border in a matrix based international environment.

olivier-boisteau

Olivier
Boisteau

Discover the biography

Olivier Boisteau

Co-Founder and Strategic Advisor, Cell Pharmacology Engineer, Ecole Pratique des Hautes Etudes, Paris IV Panthéon Sorbonne University.

As part of his degree at Sorbonne University, Olivier joins the INSERM (French National Institute of Health & Medical Research) to carry out research relating to a thesis work on colon cancer vaccination. After this initial work, he joins the team of Yannick Jacques, PhD, as engineer to a program focusing on the development of agonist/antagonist recombinant proteins to cytokine receptors. This development work was part of a larger European program. Entrepreneur at heart, Olivier then decides to venture into the business world together with Frédéric Henry and Marc Meichenin to build a company based on the expertise of mycoplasma eradication in cell cultures: Clean Cells is thus created on July 31st 2000. Olivier is also a member of the Atlanpole Biotherapies cluster’s board of directors and of AFFSSI (French Association of Service and Technological Innovation Companies).

marc-meichenin

Marc
Meichenin

Discover the biography

Marc Meichenin

Co-Founder, Board member of Clean Biologics and Chief Scientific Officer, Doctor of Biological Sciences, University of Nantes.

It was at Inserm, where he did his thesis on tumour biology, that he was led to work on cell injection in animals. Very quickly, Marc saw the importance of mycoplasma detection and focused his efforts on it, until he quickly became a reference for the institution’s researchers. In 2000, he joined the creation of Clean Cells with his two friends Olivier Boisteau and Frédéric Henry. Their joint efforts allow the development of a service company with an international aura.

Active member of ACTIP for many years and more recently appointed expert in the framework of the “Grand Défi Bioproduction”, he participates in the development of Bioproduction in France.

Since the creation of the Clean Biologics Group, which includes Clean Cells and Naobios, he brings to both entities his technical and regulatory expertise as Scientific Director.